CD19-directed CAR-T cell therapy: Class Overview and Comparison
Quick answer: CD19-directed CAR-T cell therapy are a class of medicines used for specific therapeutic indications. iMedic covers 3 cd19-directed car-t cell therapy substances. Below is a comparison table linking to detailed pages for each.
CD19-directed CAR-T cell therapy on iMedic (3 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Aucatzyl | Relapsed/refractory B-cell acute lymphoblastic leukemia | Obecabtagene autoleucel - autologous CD19-directed CAR-T cells that bind and lys | 410×10^6 CAR-positive viable T cells IV (split dose) |
| Breyanzi | Relapsed/refractory large B-cell lymphoma, Chronic lymphocytic leukemia | Brand name for lisocabtagene maraleucel; autologous CD19-directed chimeric antig | Single IV infusion of 90-110 × 10^6 CAR-positive T cells |
| Yescarta | Relapsed/refractory large B-cell lymphoma, Follicular lymphoma | Autologous CD19-targeted chimeric antigen receptor T cells that lyse CD19-expres | Single IV infusion of 2 x 10^6 CAR-positive T cells/kg |
About CD19-directed CAR-T cell therapy
CD19-directed CAR-T cell therapy share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are CD19-directed CAR-T cell therapy?
CD19-directed CAR-T cell therapy are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 3 substances in this class with detailed pages for each.
Are all CD19-directed CAR-T cell therapy interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different CD19-directed CAR-T cell therapy?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are CD19-directed CAR-T cell therapy available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.